Objectives: Tedizolid is an orally bioavailable oxazolidinone with once-daily dosing and broad-spectrum Grampositive activity. Combination therapy is commonly indicated to improve efficacy against difficult-to-treat pathogens and biofilms. There are no studies describing the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials.
Introduction
Transition from intravenous antimicrobial therapy to oral formulations during the treatment of invasive infections can help facilitate outpatient management, preventing unnecessary hospital days, and reducing the burden on outpatient parenteral antimicrobial therapy clinics and patients. 1 Unfortunately, many orally bioavailable antimicrobials are unsuitable for the management of these infections due to poor tolerability, low bioavailability or antimicrobial resistance. Tedizolid is a recently approved oxazolidinone, with high oral bioavailability, once-daily dosing regimen, and a broadspectrum of activity against Gram-positive pathogens including MRSA and VRE. Unlike linezolid, tedizolid maintains activity against linezolid non-susceptible strains harbouring the cfr plasmid, and carries lower risks of drug interactions with serotonergic compounds and the haematological toxicities often associated with prolonged linezolid use. [2] [3] [4] Consequently, tedizolid may fill a therapeutic gap where long-term, oral therapy against MDR Grampositive pathogens is desirable, such as orthopaedic infections.
For many invasive infections, especially where medical devices are involved, combination therapy is recommended to improve pharmacodynamic efficacy against biofilm-embedded organisms and reduce the probability of resistance emergence.
5 Synergistic combinations of antimicrobials may also lead to bactericidal activity, which is desirable for invasive infections such as osteomyelitis or infective endocarditis. Staphylococcus aureus and Staphylococcus epidermidis are among the most commonly identified pathogens in bone and joint infections requiring prolonged therapy. 5, 6 While tedizolid may prove useful in the management of these infections, there are currently no data available describing the synergistic or antagonistic potential of tedizolid-based antimicrobial combinations. Furthermore, there are only limited data on linezolid-based combinations as well. The existing data on oxazolidinone combinations against staphylococci are mostly limited to combinations with intravenously administered agents such as vancomycin, daptomycin or aminoglycosides. 7 These combinations fail to capitalize on a key advantage of this class of antimicrobials-the high oral bioavailability-since the companion drugs would still require intravenous (iv) administration. Therefore, the objective of this study was to investigate the pharmacodynamic interactions between tedizolid and other orally bioavailable anti-staphylococcal agents, including rifampicin, trimethoprim/sulfamethoxazole, doxycycline and moxifloxacin, against methicillin-resistant staphylococci.
Materials and methods

Media, antimicrobials and strains
Susceptibility testing and time-kill experiments were performed in MuellerHinton II broth (MHB, Becton Dickinson, Detroit, MI, USA). Tryptic soy agar (TSA) was used for subculture of organisms and colony enumeration. Tedizolid powder for in vitro use was provided by Merck (Whitehouse Station, NJ, USA). Trimethoprim, sulfamethoxazole, doxycycline, rifampicin and moxifloxacin powders were purchased commercially from Sigma. MICs of study antimicrobials were evaluated against a collection of 45 strains of staphylococci. Ten of these strains, including seven MRSA and three S. epidermidis, were evaluated in time-kill studies. These strains had various susceptibilities to the study antimicrobials and relevant alternative antimicrobials including vancomycin, daptomycin and linezolid. These strains included control strains such as N315, NRS4 and ATCC 12228, as well as clinical strains from the University of Washington Medical Center and the collection at the Anti-infective Research Lab (Wayne State University).
Susceptibility testing and time-kills
MICs were determined by broth microdilution at an inoculum of 10 6 cfu/mL in accordance with CLSI guidelines. 8 Time-kill experiments were performed in duplicate as previously described. 9,10 Briefly, 2 mL of MHB was inoculated with 10 6 cfu/mL of study organism and exposed to antimicrobial concentrations equal to 0.5 % MIC for both single and combination drug exposures. Time-kill experiments were performed over a 24 h period at 37 C with gentle shaking. Treatment included static exposures of subinhibitory concentrations of each of the following antimicrobials equal to 0.5 % MIC: tedizolid, rifampicin, trimethoprim/sulfamethoxazole, doxycycline, moxifloxacin, tedizolid ! rifampicin, tedizolid ! trimethoprim/sulfamethoxazole, tedizolid ! doxycycline and tedizolid ! moxifloxacin. The average biological free peak concentration was used instead of 0.5 % MIC when this value was lower in order to avoid overestimating the clinically achievable effect of these combinations. This may not accurately reflect the active drug concentrations in other tissues such as in bone or skin, but has been used to prevent overestimation of activity in other studies. These free peak concentrations were: doxycycline 2 mg/L, 11 Werth fluoroquinolones, such as levofloxacin, because it has been shown in a variety of studies to have more potent activity against staphylococci than levofloxacin. 15, 16 Samples of 100 lL were taken at 0, 4, 8 and 24 h in duplicate, diluted in sterile saline and spiral plated for colony enumeration using an automated colony counter (SCAN500, Interscience, France) after 24 h incubation at 37 C. Bacterial survival was expressed graphically as a function of time. Synergy was defined as a 2 log 10 cfu/mL reduction of the combination over the most active single agent, antagonism was defined as 1 log 10 cfu/mL growth compared with the most active single agent, and other interactions were indifferent.
17,18
Results
MICs of study antimicrobials for the 45 strains are summarized in Table 1 . Forty-two of the 45 strains tested were susceptible (S) to tedizolid based on current interpretive criteria (MIC ,1 mg/L). Pharmacodynamic interaction data and time-kill strain MICs are summarized in Table 2 and graphically expressed in Figure 1 . Overall, the interactions were 80% indifferent, 12.5% synergistic and 7.5% antagonistic. Synergy with tedizolid was observed in combination with rifampicin and doxycycline in 3/10 strains and 2/10 strains, respectively. Synergy was only observed when strains were susceptible to both drugs. Interactions between tedizolid and trimethoprim/sulfamethoxazole were indifferent against all 10 strains tested. Antagonism was observed when tedizolid was combined with moxifloxacin against 3/10 strains.
Discussion
In this study, the addition of tedizolid to other orally bioavailable antimicrobials resulted in pharmacodynamically 'indifferent' activity for most of the strains and drug combinations tested. Another study found that pharmacodynamic interactions between linezolid and other antibiotics were indifferent against MRSA for 26 out of 28 (92.8%) other antibiotics tested. 19 That study did not observe synergy between linezolid and tetracyclines or rifampicin against any of the MRSA strains tested. Indifferent activity is the most common finding in these types of pharmacodynamic interaction studies. Synergy is defined by robust criteria, and lack of 'true synergy' between antimicrobial combinations does not necessarily mean that there is no value in using both drugs. Nevertheless, optimal methods for, and interpretation of, synergy studies remain popular subjects for debate among experts. In this study, there was a trend towards improved activity with the combination of tedizolid plus rifampicin and tedizolid plus doxycycline compared with other combinations but this effect was not observed reliably across all strains. Unlike the combination of linezolid plus rifampicin, which is known to result in reduced clinical exposures of linezolid due to metabolic induction, tedizolid does not appear to be affected by the enzymatic induction by rifampicin, making this combination potentially useful in practice. 20 The synergy with doxycycline was unexpected since both tedizolid and doxycycline have a similar mechanism of action, targeting the ribosome. It is possible that inhibition of the ribosome at an alternative site might result in more complete inhibition of protein synthesis leading to synergy but this is only speculation. What is likely to be the most important finding of this study is that moxifloxacin was antagonistic with tedizolid in 30% of the strains tested, which may indicate that this combination should be avoided. Typically fluoroquinolones are not recommended for use against staphylococci but one can imagine how these drugs might be combined for empirical coverage of pneumonia or polymicrobial infections. Further study is warranted to confirm this finding in larger collections of strains and with other fluoroquinolones and using clinically relevant, kinetic drug exposures. Oxazolidinone-fluoroquinolone antagonism is poorly described but has been reported previously with linezolid and ciprofloxacin against S. aureus and with linezolid and ofloxacin and with linezolid and sparfloxacin against Enterococcus faecalis. 19, 21 It is unknown whether there is a specific molecular mechanism of antagonism between these agents or whether this is related to the general antagonistic effects that have been reported when bactericidal agents are combined with bacteriostatic agents. 22 Based on these data, the addition of rifampicin to tedizolid seems most likely to improve activity, but future work to evaluate the impact of these combinations on other metrics, such as resistance suppression, or on anti-biofilm efficacy, against staphylococci and other relevant pathogens, such as VRE, is warranted.
